168 related articles for article (PubMed ID: 27566592)
1. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
de Souza JG; Morais KL; Anglés-Cano E; Boufleur P; de Mello ES; Maria DA; Origassa CS; de Campos Zampolli H; Câmara NO; Berra CM; Bosch RV; Chudzinski-Tavassi AM
Oncotarget; 2016 Sep; 7(38):62255-62266. PubMed ID: 27566592
[TBL] [Abstract][Full Text] [Related]
2. Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro".
Akagi EM; Júnior PL; Simons SM; Bellini MH; Barreto SA; Chudzinski-Tavassi AM
Biomed Pharmacother; 2012 Feb; 66(1):64-9. PubMed ID: 22281290
[TBL] [Abstract][Full Text] [Related]
3. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.
Maria DA; de Souza JG; Morais KL; Berra CM; Zampolli Hde C; Demasi M; Simons SM; de Freitas Saito R; Chammas R; Chudzinski-Tavassi AM
Invest New Drugs; 2013 Jun; 31(3):493-505. PubMed ID: 22975862
[TBL] [Abstract][Full Text] [Related]
4. Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
Pacheco MT; Berra CM; Morais KL; Sciani JM; Branco VG; Bosch RV; Chudzinski-Tavassi AM
PLoS One; 2014; 9(12):e111907. PubMed ID: 25479096
[TBL] [Abstract][Full Text] [Related]
5. Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.
Pacheco MT; Morais KL; Berra CM; Demasi M; Sciani JM; Branco VG; Bosch RV; Iqbal A; Chudzinski-Tavassi AM
Exp Cell Res; 2016 Jan; 340(2):248-58. PubMed ID: 26748183
[TBL] [Abstract][Full Text] [Related]
6. Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.
Morais KL; Pacheco MT; Berra CM; Bosch RV; Sciani JM; Chammas R; de Freitas Saito R; Iqbal A; Chudzinski-Tavassi AM
Mol Cell Biochem; 2016 Apr; 415(1-2):119-31. PubMed ID: 27015684
[TBL] [Abstract][Full Text] [Related]
7. Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis.
Drewes CC; Dias RY; Hebeda CB; Simons SM; Barreto SA; Ferreira JM; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2012 Sep; 60(3):333-40. PubMed ID: 22575283
[TBL] [Abstract][Full Text] [Related]
8. A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system.
Chudzinski-Tavassi AM; De-Sá-Júnior PL; Simons SM; Maria DA; de Souza Ventura J; Batista IF; Faria F; Durães E; Reis EM; Demasi M
Toxicon; 2010 Dec; 56(7):1145-54. PubMed ID: 20570593
[TBL] [Abstract][Full Text] [Related]
9. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
10. Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells.
Schmidt MCB; Morais KLP; Almeida MES; Iqbal A; Goldfeder MB; Chudzinski-Tavassi AM
Cell Adh Migr; 2020 Dec; 14(1):129-138. PubMed ID: 30238848
[TBL] [Abstract][Full Text] [Related]
11. Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates.
Chudzinski-Tavassi AM; Morais KL; Pacheco MT; Pasqualoto KF; de Souza JG
Biomed Pharmacother; 2016 Feb; 77():14-9. PubMed ID: 26796259
[TBL] [Abstract][Full Text] [Related]
12. Post-transcriptional control of Amblyomin-X on secretion of vascular endothelial growth factor and expression of adhesion molecules in endothelial cells.
Drewes CC; Dias RY; Branco VG; Cavalcante MF; Souza JG; Abdalla DS; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2015 Jul; 101():1-10. PubMed ID: 25912945
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone induces apoptosis of human renal carcinoma Caki-1 cells by inhibiting JAK2/STAT3 through pro-oxidant effect.
Chae IG; Song NY; Kim DH; Lee MY; Park JM; Chun KS
Food Chem Toxicol; 2020 May; 139():111253. PubMed ID: 32165235
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis.
Hyun Park W; Hee Cho Y; Won Jung C; Oh Park J; Kim K; Hyuck Im Y; Lee MH; Ki Kang W; Park K
Biochem Biophys Res Commun; 2003 Jan; 300(1):230-5. PubMed ID: 12480548
[TBL] [Abstract][Full Text] [Related]
15. Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo.
Chen S; Liang L; Wang Y; Diao J; Zhao C; Chen G; He Y; Luo C; Wu X; Zhang Y
Mol Med Rep; 2015 Nov; 12(5):6727-37. PubMed ID: 26300071
[TBL] [Abstract][Full Text] [Related]
16. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
17. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
[TBL] [Abstract][Full Text] [Related]
18. GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells.
Liu SL; Liu Z; Zhang LD; Zhu HQ; Guo JH; Zhao M; Wu YL; Liu F; Gao FH
Cell Cycle; 2017; 16(24):2386-2395. PubMed ID: 28980866
[TBL] [Abstract][Full Text] [Related]
19. Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
Wu WS; Chien CC; Chen YC; Chiu WT
PLoS One; 2016; 11(8):e0160484. PubMed ID: 27483435
[TBL] [Abstract][Full Text] [Related]
20. Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance.
Kaliszczak M; Patel H; Kroll SH; Carroll L; Smith G; Delaney S; Heathcote DA; Bondke A; Fuchter MJ; Coombes RC; Barrett AG; Ali S; Aboagye EO
Br J Cancer; 2013 Oct; 109(9):2356-67. PubMed ID: 24071597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
